MITSUB.TANABE PHA.CORP. sees an upgrade to Positive due to a better fundamental star rating
The general evaluation of MITSUB.TANABE PHA.CORP. (JP), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date January 28, 2020, the closing price was JPY 2,005.00 and its potential was estimated at JPY 2,291.02.Mitsubishi Tanabe Pharma is engaged in the manufacture and sale of pharmaceutical products. Co.'s principal ethical drugs include agents for autoimmune diseases under the name of "Remicade" and "Simponi," agents for diabetes and kidney diseases under the name of "Tenelia" and "Kremezin," agents for central nervous system diseases under the name of "Ceredist," "Depas" and "Radicut" and vaccines including "Mearubik (vaccine for measles and rubella)," "TETRABIK (vaccine for diphtheria, pertussis, tetanus and polio)," influenza vaccines and varicella vaccine. Co.'s over-the-counter drugs include "Flucort f (agent for treatment of skin conditions)" and nutritional supplement drinks.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.